DK2291368T3 - Substitueret gamma-lactam som terapeutisk middel - Google Patents

Substitueret gamma-lactam som terapeutisk middel

Info

Publication number
DK2291368T3
DK2291368T3 DK09734653.0T DK09734653T DK2291368T3 DK 2291368 T3 DK2291368 T3 DK 2291368T3 DK 09734653 T DK09734653 T DK 09734653T DK 2291368 T3 DK2291368 T3 DK 2291368T3
Authority
DK
Denmark
Prior art keywords
lactam
therapeutic agent
substituted gamma
gamma
substituted
Prior art date
Application number
DK09734653.0T
Other languages
English (en)
Inventor
David W Old
Danny T Dinh
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK2291368T3 publication Critical patent/DK2291368T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK09734653.0T 2008-04-24 2009-04-22 Substitueret gamma-lactam som terapeutisk middel DK2291368T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4750108P 2008-04-24 2008-04-24
PCT/US2009/041389 WO2009132088A1 (en) 2008-04-24 2009-04-22 Substituted gamma lactams as therapeutic agents

Publications (1)

Publication Number Publication Date
DK2291368T3 true DK2291368T3 (da) 2013-03-18

Family

ID=40852537

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09734653.0T DK2291368T3 (da) 2008-04-24 2009-04-22 Substitueret gamma-lactam som terapeutisk middel

Country Status (19)

Country Link
US (1) US7820661B2 (da)
EP (1) EP2291368B1 (da)
JP (1) JP5524181B2 (da)
KR (1) KR20110008263A (da)
CN (1) CN102076681A (da)
AU (1) AU2009239372B2 (da)
BR (1) BRPI0911347A2 (da)
CA (1) CA2722529A1 (da)
CO (1) CO6321273A2 (da)
DK (1) DK2291368T3 (da)
ES (1) ES2399314T3 (da)
IL (1) IL208899A0 (da)
MX (1) MX2010011636A (da)
MY (1) MY150518A (da)
PL (1) PL2291368T3 (da)
RU (1) RU2543379C2 (da)
UA (1) UA103616C2 (da)
WO (1) WO2009132088A1 (da)
ZA (1) ZA201007553B (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
CA2534484A1 (en) 2003-08-07 2005-02-17 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using same
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8377984B2 (en) * 2008-01-29 2013-02-19 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US7842714B2 (en) * 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
WO2009129187A2 (en) * 2008-04-16 2009-10-22 Allergan, Inc. Combination therapy for glaucoma
WO2009132097A1 (en) * 2008-04-24 2009-10-29 Allergan, Inc. Substituted gamma lactams as therapeutic agents
CA2724467C (en) * 2008-05-20 2016-09-13 Allergan, Inc. Therapeutic lactams
US20100204335A1 (en) * 2008-12-01 2010-08-12 Allergan, Inc. Kit and composition for eyelash growth
KR20180021919A (ko) * 2009-11-09 2018-03-05 알러간, 인코포레이티드 모발 성장을 촉진하기 위한 조성물 및 방법
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
CN110734430A (zh) * 2012-08-21 2020-01-31 阿勒根公司 用于合成取代的γ内酰胺的方法
US9540357B1 (en) 2014-07-31 2017-01-10 Allergan, Inc. 15-aryl prostaglandins as EP4 agonists, and methods of use thereof
EP3201192B1 (en) * 2014-10-02 2019-08-21 Allergan, Inc. Ester prodrugs of gamma-lactams and their use

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US395798A (en) * 1889-01-08 reason
US4007210A (en) * 1973-04-27 1977-02-08 American Cyanamid Company Novel 3-triphenylmethoxy-1-alkynes, 3-triphenylmethoxy-1-trans-alkenyl-dialkyl-alanes, and lithium 3-triphenyl-methoxy-1-trans-alkenyl-dialkyl-alanates
US3985798A (en) 1975-01-27 1976-10-12 American Cyanamid Company 11α-HOMO-PROSTANOIC ACIDS AND ESTERS
US4060540A (en) * 1975-09-18 1977-11-29 American Cyanamid Company Novel 3-triphenylmethoxy-1-alkynes, 3-triphenyl-methoxy-1-trans-alkenyl-dialkyl-alanes, and lithium 3-triphenylmethoxy-1-trans-alkenyl-dialkyl alanates
US4166452A (en) * 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
GB2209939B (en) 1987-09-18 1992-01-02 R Tech Ueno Ltd The use of 13,14-dihydro-15-keto-prostaglandins as ocular hypotensive agents
US5028624A (en) * 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
CA2021316C (en) * 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US4994274A (en) * 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
US5288754A (en) 1992-02-04 1994-02-22 Allergan, Inc. Polar C-1 esters of prostaglandins
US5721273A (en) * 1993-12-15 1998-02-24 Alcon Laboratories, Inc. Use of certain 9-halo-13,14-dihydroprostaglandins to treat glaucoma and ocular hypertension
US5462968A (en) 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
US6034413A (en) * 1997-02-27 2000-03-07 Texas Instruments Incorporated High speed biCMOS gate power for power MOSFETs incorporating improved injection immunity
US6437146B1 (en) * 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
PL368046A1 (en) * 2001-07-16 2005-03-21 F.Hoffmann-La Roche Ag Prostaglandin analogues_as ep4 receptor agonists
KR20050039733A (ko) * 2001-11-05 2005-04-29 알러간, 인코포레이티드 ＥＰ₂-수용체 작용제로서의 ω-시클로알킬 17-헤테로아릴프로스타글란딘 Ｅ₂유사체
CA2477715A1 (en) * 2002-03-05 2003-09-12 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
US7419999B2 (en) 2002-06-10 2008-09-02 Applied Research Systems Ars Holding N.V. Gamma lactams as prostaglandin agonists and use thereof
WO2004037813A1 (en) 2002-10-25 2004-05-06 Merck Frosst Canada & Co. Pyrrolidin-2-on derivatives as ep4 receptor agonists
US7015243B2 (en) * 2003-08-28 2006-03-21 Allergan, Inc. Cyclohexyl prostaglandin analogs as EP4-receptor agonists
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
KR20070092293A (ko) * 2004-12-22 2007-09-12 얀센 파마슈티카 엔.브이. 트리사이클릭 δ-오피오이드 모듈레이터
RU2412933C2 (ru) 2005-03-10 2011-02-27 Аллерган, Инк. Замещенные гамма-лактамы в качестве терапевтических агентов
US8039507B2 (en) 2005-06-29 2011-10-18 Allergan, Inc. Therapeutic substituted gamma lactams
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
CA2645867A1 (en) * 2006-03-20 2007-09-27 Allergan, Inc. Substituted gamma lactams as prostaglandin ep2 agonists
WO2008021975A2 (en) * 2006-08-11 2008-02-21 Allergan, Inc. Therapeutic lactams
US7507817B2 (en) 2006-11-17 2009-03-24 Allergan, Inc. Prostaglandin prodrugs
AU2008210559B2 (en) * 2007-01-31 2014-03-06 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US7589213B2 (en) * 2007-04-27 2009-09-15 Old David W Therapeutic substituted lactams
WO2009132097A1 (en) * 2008-04-24 2009-10-29 Allergan, Inc. Substituted gamma lactams as therapeutic agents

Also Published As

Publication number Publication date
JP2011518833A (ja) 2011-06-30
US20090270392A1 (en) 2009-10-29
AU2009239372A1 (en) 2009-10-29
EP2291368B1 (en) 2012-12-19
ZA201007553B (en) 2011-08-31
MX2010011636A (es) 2010-11-25
IL208899A0 (en) 2011-01-31
BRPI0911347A2 (pt) 2018-03-20
RU2543379C2 (ru) 2015-02-27
UA103616C2 (ru) 2013-11-11
JP5524181B2 (ja) 2014-06-18
EP2291368A1 (en) 2011-03-09
CA2722529A1 (en) 2009-10-29
US7820661B2 (en) 2010-10-26
AU2009239372B2 (en) 2013-09-19
MY150518A (en) 2014-01-30
ES2399314T3 (es) 2013-03-27
PL2291368T3 (pl) 2013-05-31
RU2010144637A (ru) 2012-05-27
CN102076681A (zh) 2011-05-25
KR20110008263A (ko) 2011-01-26
WO2009132088A1 (en) 2009-10-29
CO6321273A2 (es) 2011-09-20

Similar Documents

Publication Publication Date Title
DK2291368T3 (da) Substitueret gamma-lactam som terapeutisk middel
DK2364293T3 (da) Hidtil ukendte pyrazol-4-N-alkoxycarboxamider som mikrobiocider
SMT201600045B (it) Composti tetraciclinici c7-fluoro sostituiti
BRPI0907457A2 (pt) Absorventes
BRPI0920521A2 (pt) combinação farmacêutica
DK2288375T3 (da) Pegylerede insulin-lispro-forbindelser
BRPI0916931A2 (pt) agentes terapêuticos
BRPI0920707A2 (pt) compostos
BRPI0908874A2 (pt) mecanismo de posicionamento de um leito
DK2242759T3 (da) Forbindelser
DK2326651T3 (da) Buprenorphinanaloger
NO20074696L (no) Aktiveringsmekanisme
BRPI0813651A2 (pt) Compostos de tiazolopiridina moduladores de sirtuína
FIC20240018I1 (fi) Vamoroloni
DK2297162T3 (da) Forbindelser
DK1987765T3 (da) Oximeter
DK2032551T3 (da) Antitumorale dihydropyran-2-on-forbindelser
DK2271618T3 (da) Farmaceutiske forbindelser
BRPI0916432A2 (pt) compostos
DK2379722T3 (da) Ekspressionsvektor
DK2206698T3 (da) Ethynylindolforbindelser
BRPI0922152A2 (pt) Compostos
DK2278899T3 (da) Bryggemekanisme
DK2323933T3 (da) Stableenhed
DK2041128T3 (da) Substituerede gamma-lactamer som terapeutiske agenser